NCT00141245已完成3 期
Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 325
- 试验地点
- 47
- 主要终点
- Safety Efficacy
研究概览
简要总结
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have met the inclusion criteria for preceding double-blind study
- •Have received double-blind study medication and wish to receive open-label pregabalin.
排除标准
- •Cannot have absence seizures
结局指标
主要结局
Safety Efficacy
次要结局
未报告次要终点
研究者
研究点 (47)
Loading locations...
相似试验
已完成
3 期
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial SeizuresSeizure Disorder, PartialNCT00141388Pfizer455
已完成
3 期
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00150293Pfizer337
已完成
3 期
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141336Pfizer750
已完成
2 期
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.Epilepsy, PartialNCT00141414Pfizer82
已完成
3 期
Pregabalin In Partial Seizures Extension StudySeizuresNCT00143130Pfizer's Upjohn has merged with Mylan to form Viatris Inc.227